HCW Biologics Inc. (HCWB) stock prices were up by 8.15% as of the market closing on October 27th 2021. This brought the price per share up to USD$2.92. Subsequent premarket fluctuations have seen the stock surge by 71.2329%, bringing it up to USD$5.00.
Do You Know The Best Place To Find Gains In Volatile Markets?
In today's chaotic marketplace, the biggest gains will come from some currently-small companies that pass by older, larger businesses still stuck in a pre-pandemic world. The trick is figuring out which small caps will be tomorrow's winners. That's why StockWire News has put together a special Wealth Building Report, highlighting 3 small cap stocks set to soar in 2023.
Click here for full details and to join for free.
HCWB Stock Gains FDA Clearance
October 28th 2021 saw HCWB stock announce having been cleared by the United States Food and Drug Administration to proceed with the evaluation of HCW9218, its lead drug candidate. This evaluation will be conducted through a first in human Phase 1b clinical trial in patients suffering from advanced pancreatic cancer. The treatment is an injectable, fusion protein complex designed to drive bifunctional, anti-tumor activity. This is facilitating by activating desired immune responses to attack cancer cells, while simultaneously blocking unwanted immunosuppressive activities.
Scope of FDA Clearance
The U.S FDA’s clearance is an important milestone for the company’s development of the first in human trial for HCW9218 in pancreatic cancer. The milestone consolidates HCWB stock’s efforts to advance the development of what could be pioneering immunotherapy candidates for cancer and other age-related diseases. Advances in immunostimulatory and anti-immunosuppressive therapeutics have revolutionized cancer treatment over the course of recent history.
HCWB Stock’s HCW9218
HCWB stock has created a bifunctional heterodimeric molecule, HCW9218, which has the ability to both stimulate the immune system and block the immunosuppressive activity of transforming growth factor- β. Preclinical studies have shown the treatment’s ability to enhance the anti-tumor efficacy of chemotherapy docetaxel and gemcitabine plus nab-paclitaxel against melanoma, and pancreatic cancer, respectively. The treatment also simultaneously alleviated the off-target, unwanted effects of chemotherapies on normal tissues.
Furthermore, the treatment was shown to augment anti-tumor activities of therapeutic and checkpoint antibodies, as demonstrated in experimental animal models. This development enhances what is current standard of care anti-cancer treatment for various solid tumors. The American Cancer Society has estimated there to be 60,430 new pancreatic cancer cases diagnosed in the United States alone.
Future Outlook for HCWB Stock
HCWB stock is poised to capitalize on the expanded scope of opportunities afforded to it by the recent development in regard to its flagship HCW9218 treatment. The company is keen to maintain the momentum generated from this development in a bid to usher further unprecedented growth. Current and potential investors are hopeful that management will be able to effectively leverage the resources at their disposal. This is hoped to facilitate consistent and organic increases in shareholder value over the long term.